Nuveen
RLMD icon

Nuveen’s Relmada Therapeutics RLMD Stock Holding History

Nuveen’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.56M Buy
+225,067
New +$1.57M ﹤0.01% 2709
2023
Q2 		– Sell
-77,379
Closed -$175K – 3279
2023
Q1 		$175K Sell
77,379
-2,779
-3% -$9.58K ﹤0.01% 3005
2022
Q4 		$280K Sell
80,158
-5,951
-7% -$52.3K ﹤0.01% 3000
2022
Q3 		$3.19M Sell
86,109
-672
-0.8% -$18.6K ﹤0.01% 2148
2022
Q2 		$1.65M Buy
86,781
+15,782
+22% +$344K ﹤0.01% 2536
2022
Q1 		$1.62M Buy
70,999
+12,333
+21% +$255K ﹤0.01% 2606
2021
Q4 		$1.32M Sell
58,666
-2,049
-3% -$45.6K ﹤0.01% 2749
2021
Q3 		$1.59M Buy
60,715
+2,427
+4% +$65K ﹤0.01% 2783
2021
Q2 		$1.87M Sell
58,288
-3,583
-6% -$124K ﹤0.01% 2748
2021
Q1 		$2.18M Buy
61,871
+2,469
+4% +$86.4K ﹤0.01% 2577
2020
Q4 		$1.91M Buy
59,402
+5,638
+10% +$194K ﹤0.01% 2538
2020
Q3 		$2.02M Sell
53,764
-3,520
-6% -$136K ﹤0.01% 2382
2020
Q2 		$2.56M Buy
+57,284
New +$2.42M ﹤0.01% 2231

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen's RLMD Position: Q2 2026 in Review

Nuveen opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 225,067 shares worth $1.56M. The stake represents ﹤0.01% of the portfolio and ranks #2709 among its holdings. This is a return to the name: Nuveen previously reported a position in RLMD as recently as Q1 2023.

Nuveen first reported a position in RLMD in Q2 2020 and has held it in 13 quarters since. The position peaked at $3.19M in Q3 2022. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Nuveen held 225,067 shares of Relmada Therapeutics worth $1.56M as of Q2 2026.
  • Relmada Therapeutics was a new Nuveen position in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2709 holding.
  • Nuveen first reported a position in Relmada Therapeutics in Q2 2020 and has held it in 13 quarters since.
  • Nuveen's Relmada Therapeutics position peaked at $3.19M in Q3 2022.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.